Drugs Approved in 2020

Ayvakit (avapritinib); Blueprint Medicines; For the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST), Approved January 2020

Tepezza (teprotumumab-trbw); Horizon Pharma Rheumatology; For the treatment of thyroid eye disease, Approved January 2020

Tazverik (tazemetostat); Epizyme Inc; For the treatment of epithelioid sarcoma, Approved January 2020

Pizensy (lactitol); Braintree Laboratories Inc; For the treatment of chronic idiopathic constipation (CIC) in adults, Approved January 2020

Drugs Approved in 2019

Accrufer (ferric maltol); Shield Therapeutics; For the treatment of iron deficiency anemia in adults, Approved July 2019

Adakveo (crizanlizumab-tmca); Shield Therapeutics; For the treatment of patients with painful complication of sickle cell disease, Approved November 2019

Balversa (erdafitinib); Janssen Oncology; For the treatment of locally advanced or metastatic urothelial carcinoma , Approved April 2019

Bavencio (avelumab) plus Inlyta (axitinib) ; Merck and Pfizer; For the first line treatment of advanced renal cell carcinoma., Approved May 2019

Beovu (brolucizumab–dbll); Novartis Pharmaceuticals Corporation; For the treatment of wet age-related macular degeneration, Approved October 2019

Brukinsa (zanubrutinib); Beigene Usa, Inc; For the treatment of certain patients with mantle cell lymphoma, a form of blood cancer, Approved November 2019

Cyramza (ramucirumab) ; Eli Lilly; For the treatment of hepatocellular carcinoma with elevated alpha-fetoprotein (AFP). Approved May 2019

Enhertu (fam-trastuzumab deruxtecan-nxki); Daiichi Sankyo Inc; For the treatment of metastatic breast cancer, Approved December 2019

Givlaari (givosiran); Alnylam Pharmaceuticals, Inc; For the treatment of acute hepatic porphyria, a rare blood disorder, Approved November 2019

Herceptin Hylecta (trastuzumab and hyaluronidase-oysk); Halozyme; For the treatment of HER2-overexpressing breast cancer. Approved February 2019

Inrebic (fedratinib); Celgene Corporation; For the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, Approved August 2019

Keytruda (pembrolizumab); Merck; For the treatment of stage III non-small cell lung cancer. Approved April 2019

Keytruda (pembrolizumab); Merck; For the treatment of advanced renal cell carcinoma. Approved April 2019

Keytruda (pembrolizumab); Merck; previously treated metastatic small cell lung cancer. Approved June 2019

Mayzent  (siponimod); Novartis Pharmaceuticals Corporation; For the treatment of adults with relapsing forms of multiple sclerosis, Approved March 2019

Nubeqa  (darolutamide); Bayer HealthCare Pharmaceuticals Inc; For the treatment of adult patients with non-metastatic castration resistant prostate cancer, Approved July 2019

Oxbryta (voxelotor); Global Blood Therapeutics Inc.; For the treatment of sickle cell disease, Approved November 2019

Padcev (enfortumab vedotin-ejfv); Seattle Genetics, Inc; For the treatment of refractory bladder cancer, Approved December 2019

Piqray (alpelisib) ; Novartis; For the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. Approved May 2019

Polivy (polatuzumab vedotin-piiq) ; Genentech; For the treatment of diffuse large B-cell lymphoma. Approved June 2019

Reblozyl  (luspatercept–aamt); Celgene; For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions, Approved November 2019

Rozlytrek  (entrectinib); Genentech Inc; For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and adult and pediatric patients 12 years of age and older with solid tumors, Approved August 2019

Tecentriq (atezolizumab); Genentech/Roche; For the treatment of extensive-stage small cell lung cancer. Approved March 2019

Tecentriq (atezolizumab); Genentech/Roche; For the treatment of triple negative breast cancer. Approved March 2019

Trikafta  (elexacaftor/ivacaftor/tezacaftor); Vertex Pharmaceuticals Incorporated; For the treatment of patients 12 years of age and older with the most common gene mutation that causes cystic fibrosis, Approved October 2019

Turalio (pexidartinib); Daiichi Sankyo Inc; For the treatment of adult patients with symptomatic tenosynovial giant cell tumor, Approved August 2019

Venclexta (venetoclax) plus Gazyva (obinutuzumab); Genentech and AbbVie; For the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma. Approved May 2019

Vyndaqel  (tafamidis meglumine); Pfizer; For the treatment of heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults, Approved May 2019

Xpovio (selinexor) ; Karyopharm Therapeutics; For the treatment of adults with relapsed or refractory multiple myeloma. Approved July 2019

Drugs Approved in 2018

Copiktra (duvelisib); Verastem; For the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma or follicular lymphoma. Approved September 2018

Daurismo (glasdegib); Pfizer; For the treatment of newly-diagnosed acute myeloid leukemia in adults 75 years of age or older. Approved November 2018

Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer. Approved February 2018

Libtayo (cemiplimab-rwlc); Regeneron Pharmaceuticals; For the treatment of cutaneous squamous cell carcinoma. Approved September 2018

Lorbrena (lorlatinib); Pfizer; For the treatment of ALK-positive metastatic non-small cell lung cancer. Approved November 2018

Lumoxiti (moxetumomab pasudotox-tdf); AstraZeneca; For the treatment of relapsed or refractory hairy cell leukemia. Approved September 2018

Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the treatment of gastroenteropancreatic neuroendocrine tumors. Approved January 2018

Poteligeo (mogamulizumab-kpkc); Kyowa Kirin; For the treatment of mycosis fungoides or Sézary syndrome. Approved August 2018

Talzenna (talazoparib); Pfizer; For the treatment of deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Approved October 2018

Vitrakvi (larotrectinib); Loxo Oncology; For the treatment of solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Approved November 2018

Vizimpro (dacomitinib); Pfizer; For the treatment of metastatic non-small cell lung cancer. Approved September 2018

Drugs Approved in 2017

Aliqopa (copanlisib); Bayer; For the treatment of follicular lymphoma. Approved September 2017

Alunbrig (brigatinib); Ariad Pharmaceuticals; For the treatment of advanced ALK-positive metastatic non-small cell lung cancer. Approved April 2017

Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma. Approved March 2017

Besponsa (inotuzumab ozogamicin); Pfizer; For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approved August 2017

Calquence (acalabrutinib); Acerta Pharmaceuticals; For the treatment of mantle cell lymphoma. Approved November 2017

Idhifa (enasidenib); Celgene; For the treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation. Approved August 2017

Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer. Initially approved May 2017

Kisqali (ribociclib); Novartis; For the treatment of breast cancer. Approved March 2017

Kymriah (tisagenlecleucel); Novartis; For the treatment of refractory B-cell precursor acute lymphoblastic leukemia. Approved August 2017

Nerlynx (neratinib); Puma Biotech; For the treatment of HER2 breast cancer, Approved July 2017

Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017

Verzenio (abemaciclib); Eli Lilly; For the treatment of HR+, HER2- breast cancer, Approved September 2017

Vyxeos (daunorubicin and cytarabine) ; Jazz Pharma; For the treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes, Approved August 2017

Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved February 2017

Yescarta (axicabtagene ciloleucel); Kite Pharmaceuticals; For the treatment of relapsed or refractory large B-cell lymphomas, Approved October 2017

Zejula (niraparib); Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017

Drugs Approved in 2016

Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma. Approved April 2016

Keytruda (pembrolizumab); Merck; For the treatment of head and neck squamous cell cancer. Approved August 2016

Lartruvo (olaratumab) ; Eli Lilly; For the treatment of soft tissue sarcoma. Approved October 2016

Lenvima (lenvatinib); Eisai; For the treatment of advanced renal cell carcinoma. Approved May 2016

Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of classical Hodgkin lymphoma. Approved May 2016

Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. Approved November 2016

Rubraca (rucaparib); Clovis Oncology; For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation. Approved December 2016

Sustol (granisetron); Heron Therapeutics; For the prevention of chemotherapy-induced nausea and vomiting. Approved August 2016

Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy. Approved July 2016

Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer. Approved May 2016

Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion. Approved April 2016

Drugs Approved in 2015

Alecensa (alectinib); Roche; For the treatment of ALK-positive, metastatic non-small cell lung cancer. Approved December 2015

Cotellic (cobimetinib) ; Genentech; For the treatment of BRAF V600E or V600K melanoma. Approved November 2015

Darzalex (daratumumab); Janssen Biotech; For the treatment of multiple myeloma. Approved November 2015

Empliciti (elotuzumab); Bristol-Myers Squibb; For the treatment of patients with multiple myeloma who have received prior therapies. Approved November 2015

Farydak (panobinostat); Novartis; For the treatment of multiple myeloma. Approved February 2015

Ibrance (palbociclib); Pfizer; For the treatment of ER-positive, HER2-negative breast cancer. Approved February 2015

Imlygic (talimogene laherparepvec) ; Amgen; For the treatment of unresectable recurrent melanoma. Approved October 2015

Keytruda (pembrolizumab); Merck; For the treatment of PD-L1 positive advanced non-small cell lung cancer. Approved October 2015

Lenvima (lenvatinib); Eisai; For the treatment of thyroid cancer. Approved February 2015

Lonsurf (trifluridine and tipiracil); Taiho Oncology; For the treatment of metastatic colorectal cancer . Approved September 2015

Ninlaro (ixazomib); Millennium Pharmaceuticals; For the treatment of multiple myeloma. Approved November 2015

Odomzo (sonidegib); Novartis; For the treatment of locally advanced basal cell carcinoma. July 2015

Onivyde (irinotecan liposome injection); Merrimack; For the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Approved October 2015

Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of advanced renal cell carcinoma. Approved November 2015

Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of metastatic squamous non-small cell lung cancer. Approved March 2015

Portrazza (necitumumab) ; Eli Lilly; For the treatment of metastatic squamous non-small cell lung cancer. Approved November 2015

Tagrisso (osimertinib); AstraZeneca; For the treatment of EGFR T790M mutation positive non-small cell lung cancer. Approved November 2015

Unituxin (dinutuximab); United Therapeutics; For the treatment of pediatrics with high-risk neuroblastoma. Approved March 2015

Varubi (rolapitant); Tesaro; For the prevention of delayed nausea and vomiting associated with chemotherapy. Approved September 2015

Vistogard (uridine triacetate); Wellstat Therapeutics; For the emergency treatment of patients with a fluorouracil or capecitabine overdose. Approved December 2015

Yondelis (trabectedin); Janssen; For the treatment of liposarcoma or leiomyosarcoma. Approved October 2015